| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $521,216 | 43 | 100 |
| Swanton Robert Charles | director | 0 | $0 | 1 | $11,906 | $-11,906 |
| Perry Jennifer Scott | Chief Operating Officer | 0 | $0 | 6 | $18,152 | $-18,152 |
| Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER | 0 | $0 | 8 | $27,912 | $-27,912 |
| Milnes Alistair | CHIEF OPERATING OFFICER | 0 | $0 | 2 | $44,127 | $-44,127 |
| Young Alethia | Chief Financial Officer | 0 | $0 | 2 | $50,489 | $-50,489 |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 0 | $0 | 8 | $57,075 | $-57,075 |
| Skynner Michael | CHIEF TECHNOLOGY OFFICER | 0 | $0 | 8 | $72,447 | $-72,447 |
| Lee Kevin | CHIEF EXECUTIVE OFFICER | 0 | $0 | 8 | $239,111 | $-239,111 |
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in …
Over the last 12 months, insiders at Bicycle Therapeutics plc have bought $0 and sold $521,216 worth of Bicycle Therapeutics plc stock.
On average, over the past 5 years, insiders at Bicycle Therapeutics plc have bought $21.23M and sold $2.31M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500,000 shares for transaction amount of $7.67M was made by BAKER BROS. ADVISORS LP () on 2024‑12‑16.
| 2026-10-05 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 1,638 0.0021% | $3.57 | $5,848 | -8.98% | |
| 2026-10-05 | Sale | Skynner Michael | CHIEF SCIENTIFIC OFFICER | 503 0.0006% | $3.57 | $1,796 | -8.98% | |
| 2026-10-05 | Sale | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 242 0.0003% | $3.57 | $864 | -8.98% | |
| 2026-10-05 | Sale | Perry Jennifer Scott | Chief Operating Officer | 356 0.0005% | $3.76 | $1,339 | -8.98% | |
| 2026-10-05 | Sale | Thompson Travis Alvin | Chief Financial Officer | 79 0.0001% | $3.57 | $282 | -8.98% | |
| 2026-10-02 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 6,167 0.0091% | $3.47 | $21,399 | +8.14% | |
| 2026-10-02 | Sale | Skynner Michael | CHIEF SCIENTIFIC OFFICER | 1,942 0.0029% | $3.47 | $6,739 | +8.14% | |
| 2026-10-02 | Sale | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 1,572 0.0023% | $3.47 | $5,455 | +8.14% | |
| 2026-10-02 | Sale | Perry Jennifer Scott | Chief Operating Officer | 1,094 0.0016% | $3.47 | $3,796 | +8.14% | |
| 2026-10-02 | Sale | Thompson Travis Alvin | Chief Financial Officer | 893 0.0013% | $3.47 | $3,099 | +8.14% | |
| 2026-10-02 | Sale | Swanton Robert Charles | director | 3,431 0.005% | $3.47 | $11,906 | +8.14% | |
| 2026-07-06 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 1,737 0.0025% | $4.31 | $7,486 | -10.34% | |
| 2026-07-06 | Sale | Skynner Michael | CHIEF SCIENTIFIC OFFICER | 532 0.0008% | $4.31 | $2,293 | -10.34% | |
| 2026-07-06 | Sale | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 255 0.0004% | $4.31 | $1,099 | -10.34% | |
| 2026-07-06 | Sale | Perry Jennifer Scott | Chief Operating Officer | 376 0.0005% | $4.34 | $1,631 | -10.34% | |
| 2026-07-06 | Sale | Thompson Travis Alvin | Chief Financial Officer | 104 0.0001% | $4.31 | $448 | -10.34% | |
| 2026-07-02 | Sale | Lee Kevin | CHIEF EXECUTIVE OFFICER | 5,905 0.0084% | $4.27 | $25,214 | -9.89% | |
| 2026-07-02 | Sale | Skynner Michael | CHIEF SCIENTIFIC OFFICER | 1,859 0.0026% | $4.27 | $7,938 | -9.89% | |
| 2026-07-02 | Sale | Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 1,506 0.0021% | $4.27 | $6,431 | -9.89% | |
| 2026-07-02 | Sale | Perry Jennifer Scott | Chief Operating Officer | 1,036 0.0015% | $4.27 | $4,424 | -9.89% |
| BAKER BROS. ADVISORS LP | 9995274 14.2804% | $36.68M | 2 | 0 | <0.0001% | |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 10 percent owner | 1957961 2.7974% | $7.19M | 1 | 0 | <0.0001% |
| HARLAND DEBORAH | director | 1915275 2.7364% | $7.03M | 1 | 0 | <0.0001% |
| GLAXOSMITHKLINE PLC | 10 percent owner | 1910531 2.7296% | $7.01M | 1 | 2 | <0.0001% |
| SVLSF V, LLC | 10 percent owner | 1875637 2.6797% | $6.88M | 1 | 0 | <0.0001% |
| Novartis Bioventures Ltd | 10 percent owner | 1769641 2.5283% | $6.49M | 1 | 0 | <0.0001% |
| Anstey Michael | director | 1751437 2.5023% | $6.43M | 1 | 0 | <0.0001% |
| Cambridge Innovation Capital (Jersey) Ltd | 10 percent owner | 1751437 2.5023% | $6.43M | 1 | 0 | <0.0001% |
| NG CAROLYN | director | 571429 0.8164% | $2.1M | 1 | 0 | <0.0001% |
| BINGHAM KATE | director | 38708 0.0553% | $142,058.36 | 1 | 2 | <0.0001% |
$60,836,085 | 69 | 0.45% | $255.44M | |
$19,239,249 | 50 | -2.24% | $238.33M | |
$109,019,806 | 28 | 7.37% | $263.86M | |
$3,668,031 | 23 | 2.05% | $243.03M | |
$2,516,932 | 19 | -15.78% | $252.7M |
| Increased Positions | 56 | +51.38% | 5M | +13.28% |
| Decreased Positions | 43 | -39.45% | 4M | -10.52% |
| New Positions | 20 | New | 3M | New |
| Sold Out Positions | 13 | Sold Out | 1M | Sold Out |
| Total Postitions | 122 | +11.93% | 39M | +2.76% |
| Baker Bros. Advisors Lp | $72,714.00 | 21.77% | 10.89M | 0 | 0% | 2025-09-30 |
| Fcpm Iii Services B.V. | $23,062.00 | 6.91% | 3.45M | 0 | 0% | 2025-09-30 |
| Armistice Capital, Llc | $19,893.00 | 5.96% | 2.98M | +178,000 | +6.36% | 2025-09-30 |
| Westfield Capital Management Co Lp | $19,723.00 | 5.91% | 2.95M | +172,052 | +6.19% | 2025-09-30 |
| Siren, L.L.C. | $13,445.00 | 4.03% | 2.01M | 0 | 0% | 2025-09-30 |
| Long Focus Capital Management, Llc | $9,477.00 | 2.84% | 1.42M | +101,402 | +7.7% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $9,250.00 | 2.77% | 1.38M | -83,599 | -5.69% | 2025-09-30 |
| Acadian Asset Management Llc | $8,781.00 | 2.63% | 1.31M | +616,055 | +88.2% | 2025-09-30 |
| Candriam S.C.A. | $7,832.00 | 2.35% | 1.17M | 0 | 0% | 2025-09-30 |
| Principal Financial Group Inc | $7,671.00 | 2.3% | 1.15M | +451,135 | +64.7% | 2025-09-30 |